keyword
https://read.qxmd.com/read/38417742/treatment-patterns-and-outcomes-in-metastatic-castration-resistant-prostate-cancer-patients-with-and-without-somatic-or-germline-alterations-in-homologous-recombination-repair-genes
#21
JOURNAL ARTICLE
D Olmos, D Lorente, D Alameda, C Cattrini, N Romero-Laorden, R Lozano, P P Lopez-Casas, A Jambrina, C Capone, A M Vanden Broecke, M Trevisan, S Van Sanden, A Jürgens, B Herrera-Imbroda, E Castro
BACKGROUND: Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in homologous recombination repair (HRR) genes and treatment outcomes in metastatic castration-resistant PC (mCRPC) is limited. The aim of this study was to investigate the prevalence and outcomes associated with somatic/germline HRR alterations, particularly BRCA1/2, in patients initiating first-line (1L) mCRPC treatment with androgen receptor signalling inhibitors (ARSi) or taxanes...
February 10, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://read.qxmd.com/read/38406993/organometallic-ru-ii-rh-iii-and-re-i-complexes-of-sterane-based-bidentate-ligands-synthesis-solution-speciation-interaction-with-biomolecules-and-anticancer-activity
#22
JOURNAL ARTICLE
Tamás Pivarcsik, Márton A Kiss, Uroš Rapuš, Jakob Kljun, Gabriella Spengler, Éva Frank, Iztok Turel, Éva A Enyedy
In this study, we present the synthesis, characterization and in vitro cytotoxicity of six organometallic [Ru(II)(η6 - p -cymene)( N , N )Cl]Cl, [Rh(III)(η5 -C5 Me5 )( N , N )Cl]Cl and [Re(I)(CO)3 ( N , N )Cl] complexes, in which the ( N , N ) ligands are sterane-based 2,2'-bipyridine derivatives (4-Me-bpy-St-OH, 4-Ph-bpy-St-OH). The solution chemical behavior of the ligands and the complexes was explored by UV-visible spectrophotometry and 1 H NMR spectroscopy. The ligands and their Re(I) complexes are neutral at pH = 7...
February 26, 2024: Dalton Transactions: An International Journal of Inorganic Chemistry
https://read.qxmd.com/read/38392072/contemporary-systemic-therapy-intensification-for-prostate-cancer-a-review-for-general-practitioners-in-oncology
#23
REVIEW
Anupam Batra, Daniel Glick, Mario Valdes
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand therapy or combination strategies in addition to androgen deprivation therapy. In this review, we summarize the available data addressing key therapeutic areas along the disease continuum and focus on practical aspects for general practitioners in oncology managing patients with metastatic prostate cancer...
February 15, 2024: Current Oncology
https://read.qxmd.com/read/38383139/increased-pi3k-pathway-activity-is-associated-with-recurrent-breast-cancer-in-patients-with-low-and-intermediate-21-gene-recurrence-score
#24
JOURNAL ARTICLE
Lawrence Hsu Lin, Yvonne Wesseling-Rozendaal, Varshini Vasudevaraja, Guomiao Shen, Margaret Black, Dianne van Strijp, Sigi Neerken, Paul A van de Wiel, George Jour, Paolo Cotzia, Farbod Darvishian, Matija Snuderl
AIMS: We investigated key signalling pathways' activity and mutational status of early-stage breast carcinomas with low and intermediate 21-gene recurrence score (RS) to identify molecular features that may predict recurrence. METHODS: This is a retrospective case-control study of 18 patients with recurrent breast carcinoma with low and intermediate 21-gene RS (<25) and control group of 15 non-recurrent breast cancer patients. DNA and mRNA were extracted from tumour tissue...
February 21, 2024: Journal of Clinical Pathology
https://read.qxmd.com/read/38377363/reversibility-of-bicalutamide-psma-pet-positive-gynecomastia-with-androgen-deprivation-therapy
#25
JOURNAL ARTICLE
Miguel Muniz, Daniel S Childs, Jacob J Orme, Geoffrey B Johnson, Oliver Sartor
A 78-year-old man receiving bicalutamide for prostate cancer was referred for a PSMA PET/CT scan to evaluate his gradually rising prostate-specific antigen level. The PSMA PET/CT revealed gynecomastia with radiotracer uptake in bilateral breast parenchyma, a known but rarely reported effect of bicalutamide monotherapy. This scan also demonstrated metastatic progression of his disease in bone and lymph nodes, and he was started on leuprolide injections. Three months after a decrease in his testosterone level, the radiotracer uptake in his breast tissue had resolved, demonstrating that PSMA-avid bicalutamide-induced gynecomastia is reversible...
February 7, 2024: Clinical Nuclear Medicine
https://read.qxmd.com/read/38374890/association-of-androgen-receptor-and-tumour-infiltrating-lymphocytes-with-bone-recurrence-in-triple-negative-breast-cancer
#26
JOURNAL ARTICLE
Petra Ilenič, Ajda Herman, Erik Langerholc, Barbara Gazić, Boštjan Šeruga
BACKGROUND: As compared to endocrine responsive breast cancer bone is less frequent site of distant recurrence in triple-negative breast cancer (TNBC). A biomarker which predicts bone recurrence would allow a more personalized treatment approach with adjuvant bisphosphonates in TNBC. Here we hypothesised that tumour expression of androgen receptor (AR) is associated with bone recurrence in TNBC. MATERIALS AND METHODS: Patients with operable TNBC who were treated at the Institute of Oncology Ljubljana between 2005 and 2015 and developed distant recurrence were included into our study...
February 2024: Journal of Bone Oncology
https://read.qxmd.com/read/38366725/analysis-of-the-responsiveness-to-antiandrogens-in-multiple-breast-cancer-cell-lines
#27
JOURNAL ARTICLE
Yuka Kuroiwa, Kagenori Ito, Jun Nakayama, Kentaro Semba, Yusuke Yamamoto
Antiandrogens were originally developed as therapeutic agents for prostate cancer but are also expected to be effective for breast cancer. However, the role of androgen signaling in breast cancer has long been controversial due to the limited number of experimental models. Our study aimed to comprehensively investigate the efficacy of antiandrogens on breast cancer. In the present study, a total of 18 breast cancer cell lines were treated with the agonist or antagonists of the androgen receptor (AR). Among the 18 cell lines tested, only T-47D cells proliferated in an androgen-dependent manner, while the other cell lines were almost irresponsive to AR stimulation...
February 17, 2024: Genes to Cells: Devoted to Molecular & Cellular Mechanisms
https://read.qxmd.com/read/38363402/sex-steroid-hormones-and-risk-of-postmenopausal-estrogen-receptor-positive-breast-cancer-a-case-cohort-analysis
#28
JOURNAL ARTICLE
Frances E M Albers, Makayla W C Lou, S Ghazaleh Dashti, Christopher T V Swain, Sabina Rinaldi, Vivian Viallon, Amalia Karahalios, Kristy A Brown, Marc J Gunter, Roger L Milne, Dallas R English, Brigid M Lynch
PURPOSE: Sex-steroid hormones are associated with postmenopausal breast cancer but potential confounding from other biological pathways is rarely considered. We estimated risk ratios for sex-steroid hormone biomarkers in relation to postmenopausal estrogen receptor (ER)-positive breast cancer, while accounting for biomarkers from insulin/insulin-like growth factor-signaling and inflammatory pathways. METHODS: This analysis included 1208 women from a case-cohort study of postmenopausal breast cancer within the Melbourne Collaborative Cohort Study...
February 16, 2024: Cancer Causes & Control: CCC
https://read.qxmd.com/read/38362126/sex-specific-outcomes-in-cancer-therapy-the-central-role-of-hormones
#29
REVIEW
Parisa Bakhshi, Jim Q Ho, Steven Zanganeh
Sex hormones play a pivotal role in modulating various physiological processes, with emerging evidence underscoring their influence on cancer progression and treatment outcomes. This review delves into the intricate relationship between sex hormones and cancer, elucidating the underlying biological mechanisms and their clinical implications. We explore the multifaceted roles of estrogen, androgens, and progesterone, highlighting their respective influence on specific cancers such as breast, ovarian, endometrial, and prostate...
2024: Frontiers in medical technology
https://read.qxmd.com/read/38349455/investigating-the-immunological-function-of-alpha-2-glycoprotein-1-zinc-binding-in-regulating-tumor-response-in-the-breast-cancer-microenvironment
#30
JOURNAL ARTICLE
Toru Hanamura, Kozue Yokoyama, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi, Jennifer K Richer, Naoki Niikura
BACKGROUND: Alpha-2-glycoprotein 1, zinc-binding (ZAG), a secreted protein encoded by the AZGP1 gene, is structurally similar to HLA class I. Despite its presumed immunological function, little is known about its role in tumor immunity. In this study, we thus aimed to determine the relationship between the expression of AZGP1/ZAG and the immunological profiles of breast cancer tissues at both the gene and protein level. METHODS: Using a publicly available gene expression dataset from a large-scale breast cancer cohort, we conducted gene set enrichment analysis (GSEA) to screen the biological processes associated with AZGP1...
February 13, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38342115/activity-and-safety-of-enobosarm-a-novel-oral-selective-androgen-receptor-modulator-in-androgen-receptor-positive-oestrogen-receptor-positive-and-her2-negative-advanced-breast-cancer-study-g200802-a-randomised-open-label-multicentre-multinational-parallel-design
#31
JOURNAL ARTICLE
Carlo Palmieri, Hannah Linden, Stephen N Birrell, Sally Wheelwright, Elgene Lim, Lee S Schwartzberg, Amy R Dwyer, Theresa E Hickey, Hope S Rugo, Patrick Cobb, Joyce A O'Shaughnessy, Stephen Johnston, Adam Brufsky, Wayne D Tilley, Beth Overmoyer
BACKGROUND: The androgen receptor is a tumour suppressor in oestrogen receptor-positive breast cancer. The activity and safety of enobosarm, an oral selective androgen receptor modulator, was evaluated in women with oestrogen receptor (ER)-positive, HER2-negative, and androgen receptor (AR)-positive disease. METHODS: Women who were postmenopausal (aged ≥18 years) with previously treated ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled in a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial done at 35 cancer treatment centres in nine countries...
February 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38342112/androgen-receptor-agonism-in-advanced-oestrogen-receptor-positive-breast-cancer
#32
JOURNAL ARTICLE
Nan Chen, Rita Nanda
No abstract text is available yet for this article.
February 8, 2024: Lancet Oncology
https://read.qxmd.com/read/38339416/micrornas-associated-with-androgen-receptor-and-metastasis-in-triple-negative-breast-cancer
#33
JOURNAL ARTICLE
Mamoun Ahram, Bayan Abu Alragheb, Hassan Abushukair, Randa Bawadi, Maysa Al-Hussaini
It is crucial to identify novel molecular biomarkers and therapeutic targets for triple-negative breast cancer (TNBC). The androgen receptor (AR) is a regulator of TNBC, acting partially via microRNA molecules (miRNAs). In this study, we used PCR arrays to profile the expression of 84 miRNAs in 24 TNBC tissue samples, which were equally classified according to AR expression and/or metastasis. Several bioinformatics tools were then utilized to determine the potentially affected protein targets and signaling pathways...
February 4, 2024: Cancers
https://read.qxmd.com/read/38339092/treatments-targeting-the-androgen-receptor-and-its-splice-variants-in-breast-cancer
#34
REVIEW
Amy H Tien, Marianne D Sadar
Breast cancer is a major cause of death worldwide. The complexity of endocrine regulation in breast cancer may allow the cancer cells to escape from a particular treatment and result in resistant and aggressive disease. These breast cancers usually have fewer treatment options. Targeted therapies for cancer patients may offer fewer adverse side effects because of specificity compared to conventional chemotherapy. Signaling pathways of nuclear receptors, such as the estrogen receptor (ER), have been intensively studied and used as therapeutic targets...
February 2, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38338747/androgen-and-estrogen-%C3%AE-receptor-expression-enhances-efficacy-of-antihormonal-treatments-in-triple-negative-breast-cancer-cell-lines
#35
JOURNAL ARTICLE
Belen Crespo, Juan Carlos Illera, Gema Silvan, Paula Lopez-Plaza, María Herrera de la Muela, Miriam de la Puente Yagüe, Cristina Diaz Del Arco, Maria Jose Illera, Sara Caceres
The triple-negative breast cancer (TNBC) subtype is characterized by the lack of expression of ERα (estrogen receptor α), PR (progesterone receptor) and no overexpression of HER-2. However, TNBC can express the androgen receptor (AR) or estrogen receptor β (ERβ). Also, TNBC secretes steroid hormones and is influenced by hormonal fluctuations, so the steroid inhibition could exert a beneficial effect in TNBC treatment. The aim of this study was to evaluate the effect of dutasteride, anastrozole and ASP9521 in in vitro processes using human TNBC cell lines...
January 25, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38331103/in-vitro-assessment-of-potential-endocrine-disrupting-activities-of-chlorinated-paraffins-of-various-chain-lengths
#36
JOURNAL ARTICLE
Mikala Melchiors, Kieu-Mi Tran, Terje Svingen, Anna Kjerstine Rosenmai
The production of chlorinated paraffins (CPs) has risen in the past two decades due to their versatile industrial applications. Consequently, CPs are now widely detected in human food sources, the environment, and in human matrices such as serum, the placenta and breast milk. This raises concern about prenatal and postnatal exposure. While some studies suggest that certain short-chained CPs (SCCPs) may have endocrine disrupting properties, knowledge about potential endocrine disrupting potential of medium- (MCCP) and long-chained CPs (LCCPs) remains relativity sparse...
February 6, 2024: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/38327829/complexities-in-adjuvant-endocrine-therapy-for-breast-cancer-in-female-to-male-transgender-patients
#37
Shoko Sato, Sae Imada, Ryosuke Hayami, Kazumori Arai, Rieko Kosugi, Michiko Tsuneizumi, Ryoichi Matsunuma
INTRODUCTION: Managing breast cancer in female-to-male (FtM) transgender patients is complicated and challenging. Androgens play a crucial role in the development of secondary sexual identity in FtM transgender patients, but their effectiveness in breast cancer remains unclear. Furthermore, the considerations for adjuvant endocrine therapy in this population are highly intricate and warrant thorough discussion. CASE PRESENTATION: We describe the case of a 44-year-old FtM transgender diagnosed with breast cancer 3 years after initiating androgen receptor agonist therapy as part of his gender identity transition...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38317241/the-androgen-receptor-interacts-with-gata3-to-transcriptionally-regulate-a-luminal-epithelial-cell-phenotype-in-breast-cancer
#38
JOURNAL ARTICLE
Leila Hosseinzadeh, Zoya Kikhtyak, Geraldine Laven-Law, Stephen M Pederson, Caroline G Puiu, Clive S D'Santos, Elgene Lim, Jason S Carroll, Wayne D Tilley, Amy R Dwyer, Theresa E Hickey
BACKGROUND: The androgen receptor (AR) is a tumor suppressor in estrogen receptor (ER) positive breast cancer, a role sustained in some ER negative breast cancers. Key factors dictating AR genomic activity in a breast context are largely unknown. Herein, we employ an unbiased chromatin immunoprecipitation-based proteomic technique to identify endogenous AR interacting co-regulatory proteins in ER positive and negative models of breast cancer to gain new insight into mechanisms of AR signaling in this disease...
February 5, 2024: Genome Biology
https://read.qxmd.com/read/38311094/filamin-a-in-triple-negative-breast-cancer
#39
REVIEW
Pia Giovannelli, Marzia Di Donato, Fabrizio Licitra, Emilia Sabbatino, Viviana Tutino, Gabriella Castoria, Antimo Migliaccio
Triple-negative breast cancer is a rare but highly heterogeneous breast cancer subtype with a limited choice of specific treatments. Chemotherapy remains the only efficient treatment, but its side effects and the development of resistance consolidate the urgent need to discover new targets. In TNBC, filamin A expression correlates to grade and TNM stage. Accordingly, this protein could constitute a new target for this BC subtype. Even if most of the data indicates its direct involvement in cancer progression, some contrasting results underline the need to deepen the studies...
February 2, 2024: Steroids
https://read.qxmd.com/read/38279500/increased-risk-of-ovarian-and-breast-malignancies-in-women-with-polycystic-ovary-syndrome-a-review-article
#40
REVIEW
Huiqing Chen, Qian Jiang, Yanru Yin
Polycystic ovary syndrome (PCOS) is one of the common abnormalities in 5 to 8% of reproductive-age women, which is associated with high levels of androgens and polycystic ovaries. A clear connection between the level of sex hormones and some women's cancers and infertility abnormalities has been identified. Investigating common mutations in ovarian and breast cancer in people with PCOS can help to better understand the risk and their relationship. Epidemiological data suggest that the induction and biology of breast and ovarian cancer are related to estrogen levels...
December 20, 2023: Cellular and Molecular Biology
keyword
keyword
91265
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.